Predicted impact of HPV vaccination and primary HPV screening on precancer treatment rates and adverse pregnancy outcomes in Australia 2010–2070: Modelling in a high income, high vaccination coverage country with HPV-based cervical screening
This analysis demonstrates that the benefits of HPV vaccination programs extend beyond prevention of HPV-related disease. HPV vaccination will reduce PTBs and LBW infants, with a further reduction with future twice-lifetime screening for HPV9 cohorts.
Authors
- Louiza S. Velentzis (ORCID: https://orcid.org/0000-0002-9309-0492)
- Karen Canfell (ORCID: https://orcid.org/0000-0002-6443-6618)
- Deborah Bateson (ORCID: https://orcid.org/0000-0003-1035-7110)
- Gigi Lui
- Michaela Hall (ORCID: https://orcid.org/0000-0002-8989-1449)
- Megan A. Smith (ORCID: https://orcid.org/0000-0002-0401-2653)
- C. David Wrede (ORCID: https://orcid.org/0000-0002-2624-9061)
- Michael Caruana (ORCID: https://orcid.org/0000-0002-5439-6552)
- Susan Yuill (ORCID: https://orcid.org/0000-0001-7609-972X)
Institutions
- The University of Sydney (AU)
- The Royal Melbourne Hospital (AU)
- Royal Women's Hospital (AU)
- Cancer Council NSW (AU)
Publication Details
- Journal
- Vaccine
- Published
- 2025-03-15
- DOI
- https://doi.org/10.1016/j.vaccine.2025.126986
- Citations
- 3
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 4.06
Funders
- Cancer Institute NSW
- National Health and Medical Research Council
- Cancer Council NSW